gary phillips
- Home
- gary phillips
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti launches new payments platform for purpose-issued Visa cards
- Review
- September 29, 2020
Latest Articles
Cancer drug development company gathering momentum as more researchers worldwide take notice
With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead MorePublic
Small Caps Watch: Pharmaxis CEO Gary Phillips
Sitting down with Gary Phillips reminds me of chatting to my favourite chemistry teacher in high school. Not that you’d usually compare a biotech company CEO to a past teacher but much like Mr McLeod, Gary has the unique ability to get you excited about science. Gary heads up Pharmaxis (ASX: PXS), a Sydney-based biotechnologyRead MorePublic
First cohort responds well to Pharmaxis cancer treatment drug – next phase of clinical trial fully subscribed
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read MorePublic
Pharmaxis streamlines operations with $2m sale of Russian distribution rights
Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up its cash position via the sale of distribution rights in Russia for their cystic fibrosis treatment which is gathering international momentum. The deal will send exclusive distribution rights in Russia to specialty company GEN İlaç
Read MorePublic
Pharmaxis shares present untapped value as the drug developer pursues a rare cancer therapy
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one. In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million
Read MorePublic
Pharmaxis targeting scar-free recovery from burns with world-first trials
One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read MorePublic
- 1
- 2